Singapore, May 21 -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced that its commercial partner in Japan, Yoshindo Inc., has launchedUstekinumab BS Subcutaneous Injection [YD], a biosimilar to the reference product Stelara(R) (ustekinumab).

The biosimilar ustekinumab, developed and manufactured by Biocon Biologics, is commercialised and marketed in Japan by Yoshindo Inc.

Ustekinumab, a monoclonal antibody, is approved for the treatment ofpsoriasis vulgarisandpsoriatic arthritis (PsA).

In April 2024, the company entered into a settlement and licensing agreementwith Janssen Biotech Inc., Janssen Sciences Ireland, and Johnson & Johnson (collectively known as Janssen) t...